{"id":20267993,"updated":"2026-09-28T15:19:32Z","additionalIndexing":"2841","affairType":{"abbreviation":"Fra.","id":14,"name":"Fragestunde. Frage"},"author":{"councillor":{"code":3024,"gender":"m","id":4118,"name":"Lohr Christian","officialDenomination":"Lohr"},"faction":{"abbreviation":"Fraktion M-E","code":"M-E","id":3,"name":"Die Mitte-Fraktion. Die Mitte. EVP."},"type":"author"},"deposit":{"council":{"abbreviation":"NR","id":1,"name":"Nationalrat","type":"N"},"date":"2026-09-23T00:00:00Z","legislativePeriod":52,"session":"5215"},"descriptors":[],"drafts":[{"consultation":{"resolutions":[{"category":{"id":3,"name":"Normal"},"council":{"abbreviation":"NR","id":1,"name":"Nationalrat","type":"N"},"date":"2026-09-28T00:00:00Z","text":"Mündliche Beantwortung der Frage","type":82}]},"federalCouncilProposal":{},"index":0,"links":[],"preConsultations":[],"references":[],"relatedDepartments":[{"abbreviation":"EDI","id":4,"name":"Departement des Innern","leading":true}],"states":[{"date":"\/Date(1790114400000+0200)\/","id":202,"name":"Eingereicht"},{"date":"\/Date(1790546400000+0200)\/","id":229,"name":"Erledigt"}],"texts":[]}],"language":"de","priorityCouncils":[{"abbreviation":"NR","id":1,"name":"Nationalrat","type":"N","priority":1}],"relatedAffairs":[],"roles":[{"councillor":{"code":3024,"gender":"m","id":4118,"name":"Lohr Christian","officialDenomination":"Lohr"},"faction":{"abbreviation":"Fraktion M-E","code":"M-E","id":3,"name":"Die Mitte-Fraktion. Die Mitte. EVP."},"type":"author"}],"shortId":"26.7993","state":{"id":229,"name":"Erledigt","doneKey":"0","newKey":1},"texts":[{"type":{"id":5,"name":"Eingereichter Text"},"value":"<p>Der Bundesrat spricht von 70% Verfügbarkeit bei Orphan Drugs. Der EFPIA W.A.I.T. Indicator zeigt, dass nur 38% in der Schweiz voll öffentlich verfügbar sind. Damit belegt die Schweiz Platz 9.<br>- Sind für den Bundesrat Einzelfallvergütungen und eingeschränkte Zugangsformen mit einem regulären Patientenzugang gleichzusetzen?&nbsp;<br>- Wenn nein: Welche konkrete Zielgrösse setzt sich der Bundesrat für den vollen öffentlich vergüteten Zugang zu Orphan Drugs und bis wann soll diese erreicht werden?<\/p>"},{"type":{"id":1,"name":"Titel des Geschäftes"},"value":"Zielgrösse bei Zugang zu Orphan Drugs?"}],"title":"Zielgrösse bei Zugang zu Orphan Drugs?"}